IS There an Impact of PAI-1 on the Thrombotic Episode in Iraqi Obese Patients with Corona Virus -19

Abstract

Objective: firstly To assess the incidence of Corona Virus -19 covid-19 as risk factors in obese individuals
leading to thrombotic episode, and secondly to compare the effects Plasminogen activator inhibitor-1 (PAI-1)
on the occurrence of this thrombotic status in obese and normal body weight individuals. The pathogenesis
of Coronavirus disease 2019 (COVID-19) is gradually demonstrated and explained around the world A high
and a great number of thrombotic episodes are reported, in present study can be consider the COVID-19 as
a prothrombotic disease.
Design and Methods: The experiments comparing the PAI-1 in 90 obese and 30 normal body weight
participants aged 32-62 years. The obese patients subdivided to three groups: first group consisted from 30
over weight individuals and the second group comprised from 30 obese patients, while third group consisted
from 30 morbid obesity patients. All participants underwent to the medical examinations to make sure they
were infected with covid-19. The activity of PAI-1and tissue plasminogen activator (t-PA) was determined
by applied ELISA method by certain kit in all study groups individuals.
Results: Three study groups (overweight, obese, and morbid obesity) elicited significant (p< 0.05) elevation
in metabolic characteristics such as fasting blood glucose (FBG), fasting insulin and lipids variables, as well
as increasing in insulin resistance (HOMA-IR) and D-dimer fractions, in addition to there were significant
augmentation in PAI-1 and t-PA in three study groups when comparing with those of normal or healthy body
weight
The present results show a positive relationship between PAI-1 and body mass index, t-PA, D-dimer and
metabolic characteristics which include fasting blood glucose, fasting insulin and lipids fractions, also
HOMA-IR.